immunohistochemical images (Human Protein Atlas)
86
Structured Review
Human Protein Atlas
immunohistochemical images
Immunohistochemical Images, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+images/images+immunohistochemical/pmc13247677-155-0-5
Average 86 stars, based on 1 article reviews
Immunohistochemical Images, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc+images/images+immunohistochemical/pmc13247677-155-0-5
Average 86 stars, based on 1 article reviews
immunohistochemical images - by Bioz Stars,
2026-09
86/100 stars
Images
1) Product Images from "LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches"
Article Title: LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches
Journal: Oncology Letters
doi: 10.3892/ol.2026.15671
Figure Legend Snippet: Comprehensive expression analysis of LATS2 in LUAD and LUSC. (A) Expression levels of LATS2 in LUAD and LUSC analyzed using the Gene Set Cancer Analysis platform. (B) Comparative analysis of LATS2 expression between tumor and normal tissues in LUAD using independent sample t-test and paired sample t-test. (C) Comparative analysis of LATS2 expression between tumor and normal tissues in LUSC using independent sample t-test and paired sample t-test. (D) Differential expression of LATS2 between LUAD and LUSC tumor tissues. (E) Immunohistochemical validation of LATS2 expression in LUAD, LUSC and normal lung tissues using the Human Protein Atlas database (antibody ID: 039191). All the data are presented as mean ± SD. ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TPM, transcripts per million; RSEM, RNA-seq by expectation-maximization.
Techniques Used: Expressing, Quantitative Proteomics, Immunohistochemical staining, Biomarker Discovery, RNA Sequencing
Related Articles
Immunohistochemistry:Article Title: Identification of immune-related gene signature for predicting prognosis of glioblastoma patients Article Snippet: .. Article Title: TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation Article Snippet: .. We next queried The Human Protein Atlas (HPA) for breast/breast-cancer specimens and incorporated IRB-approved clinical paraffin sections from our center to obtain Article Title: Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression Article Snippet: .. Protein expression and Article Title: Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma Article Snippet: .. All Article Title: Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression Article Snippet: .. Consistent with Article Title: Celastrol induces ferroptosis in ccRCC through TEF-Driven ACOX2 upregulation and metabolic reprogramming. Article Snippet: .. ACOX2 is identified as a key mediator of celastrol-induced cytotoxicity in ccRCC cells. (A–B) RNA sequencing of 786-O and 769-P cells treated with celastrol or DMSO identifying differentially expressed genes; (C) GO enrichment analysis of celastrol target genes from CTD showing significant enrichment in metabolic pathways; (D) Venn diagram integrating metabolic pathway–related genes from GeneCards with differentially expressed genes in ccRCC cells after CEL treatment (CEL DEGs) and DEGs from TCGA KIRC cohort (KIRC DEGs), yielding 27 overlapping candidates; (E) Cytoscape-based network analysis of the 27 candidate genes revealing functional clusters including lipid metabolic regulation; (F) Prognostic analysis of 24 candidate genes (three not available in GSCA) using TCGA-KIRC data showing associations with OS and PFS; (G–H) Expression analysis demonstrating reduced ACOX2 expression in ccRCC tissues compared with normal kidney tissues, confirmed in paired samples; (I) Kaplan–Meier survival curves showing higher ACOX2 expression associated with improved OS and PFS in KIRC patients; (J) Human Protein Atlas Article Title: TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation. Article Snippet: .. We next queried The Human Protein Atlas (HPA) for breast/breast-cancer specimens and incorporated IRB-approved clinical paraffin sections from our center to obtain Article Title: Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma. Article Snippet: .. All Selection:Article Title: Identification of immune-related gene signature for predicting prognosis of glioblastoma patients Article Snippet: .. Staining:Article Title: Identification of immune-related gene signature for predicting prognosis of glioblastoma patients Article Snippet: .. Article Title: Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma Article Snippet: .. All Article Title: Celastrol induces ferroptosis in ccRCC through TEF-Driven ACOX2 upregulation and metabolic reprogramming. Article Snippet: .. ACOX2 is identified as a key mediator of celastrol-induced cytotoxicity in ccRCC cells. (A–B) RNA sequencing of 786-O and 769-P cells treated with celastrol or DMSO identifying differentially expressed genes; (C) GO enrichment analysis of celastrol target genes from CTD showing significant enrichment in metabolic pathways; (D) Venn diagram integrating metabolic pathway–related genes from GeneCards with differentially expressed genes in ccRCC cells after CEL treatment (CEL DEGs) and DEGs from TCGA KIRC cohort (KIRC DEGs), yielding 27 overlapping candidates; (E) Cytoscape-based network analysis of the 27 candidate genes revealing functional clusters including lipid metabolic regulation; (F) Prognostic analysis of 24 candidate genes (three not available in GSCA) using TCGA-KIRC data showing associations with OS and PFS; (G–H) Expression analysis demonstrating reduced ACOX2 expression in ccRCC tissues compared with normal kidney tissues, confirmed in paired samples; (I) Kaplan–Meier survival curves showing higher ACOX2 expression associated with improved OS and PFS in KIRC patients; (J) Human Protein Atlas Article Title: Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma. Article Snippet: .. All Expressing:Article Title: Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression Article Snippet: .. Protein expression and Article Title: Celastrol induces ferroptosis in ccRCC through TEF-Driven ACOX2 upregulation and metabolic reprogramming. Article Snippet: .. ACOX2 is identified as a key mediator of celastrol-induced cytotoxicity in ccRCC cells. (A–B) RNA sequencing of 786-O and 769-P cells treated with celastrol or DMSO identifying differentially expressed genes; (C) GO enrichment analysis of celastrol target genes from CTD showing significant enrichment in metabolic pathways; (D) Venn diagram integrating metabolic pathway–related genes from GeneCards with differentially expressed genes in ccRCC cells after CEL treatment (CEL DEGs) and DEGs from TCGA KIRC cohort (KIRC DEGs), yielding 27 overlapping candidates; (E) Cytoscape-based network analysis of the 27 candidate genes revealing functional clusters including lipid metabolic regulation; (F) Prognostic analysis of 24 candidate genes (three not available in GSCA) using TCGA-KIRC data showing associations with OS and PFS; (G–H) Expression analysis demonstrating reduced ACOX2 expression in ccRCC tissues compared with normal kidney tissues, confirmed in paired samples; (I) Kaplan–Meier survival curves showing higher ACOX2 expression associated with improved OS and PFS in KIRC patients; (J) Human Protein Atlas RNA Sequencing:Article Title: Celastrol induces ferroptosis in ccRCC through TEF-Driven ACOX2 upregulation and metabolic reprogramming. Article Snippet: .. ACOX2 is identified as a key mediator of celastrol-induced cytotoxicity in ccRCC cells. (A–B) RNA sequencing of 786-O and 769-P cells treated with celastrol or DMSO identifying differentially expressed genes; (C) GO enrichment analysis of celastrol target genes from CTD showing significant enrichment in metabolic pathways; (D) Venn diagram integrating metabolic pathway–related genes from GeneCards with differentially expressed genes in ccRCC cells after CEL treatment (CEL DEGs) and DEGs from TCGA KIRC cohort (KIRC DEGs), yielding 27 overlapping candidates; (E) Cytoscape-based network analysis of the 27 candidate genes revealing functional clusters including lipid metabolic regulation; (F) Prognostic analysis of 24 candidate genes (three not available in GSCA) using TCGA-KIRC data showing associations with OS and PFS; (G–H) Expression analysis demonstrating reduced ACOX2 expression in ccRCC tissues compared with normal kidney tissues, confirmed in paired samples; (I) Kaplan–Meier survival curves showing higher ACOX2 expression associated with improved OS and PFS in KIRC patients; (J) Human Protein Atlas Functional Assay:Article Title: Celastrol induces ferroptosis in ccRCC through TEF-Driven ACOX2 upregulation and metabolic reprogramming. Article Snippet: .. ACOX2 is identified as a key mediator of celastrol-induced cytotoxicity in ccRCC cells. (A–B) RNA sequencing of 786-O and 769-P cells treated with celastrol or DMSO identifying differentially expressed genes; (C) GO enrichment analysis of celastrol target genes from CTD showing significant enrichment in metabolic pathways; (D) Venn diagram integrating metabolic pathway–related genes from GeneCards with differentially expressed genes in ccRCC cells after CEL treatment (CEL DEGs) and DEGs from TCGA KIRC cohort (KIRC DEGs), yielding 27 overlapping candidates; (E) Cytoscape-based network analysis of the 27 candidate genes revealing functional clusters including lipid metabolic regulation; (F) Prognostic analysis of 24 candidate genes (three not available in GSCA) using TCGA-KIRC data showing associations with OS and PFS; (G–H) Expression analysis demonstrating reduced ACOX2 expression in ccRCC tissues compared with normal kidney tissues, confirmed in paired samples; (I) Kaplan–Meier survival curves showing higher ACOX2 expression associated with improved OS and PFS in KIRC patients; (J) Human Protein Atlas Biomarker Discovery:Article Title: Celastrol induces ferroptosis in ccRCC through TEF-Driven ACOX2 upregulation and metabolic reprogramming. Article Snippet: .. ACOX2 is identified as a key mediator of celastrol-induced cytotoxicity in ccRCC cells. (A–B) RNA sequencing of 786-O and 769-P cells treated with celastrol or DMSO identifying differentially expressed genes; (C) GO enrichment analysis of celastrol target genes from CTD showing significant enrichment in metabolic pathways; (D) Venn diagram integrating metabolic pathway–related genes from GeneCards with differentially expressed genes in ccRCC cells after CEL treatment (CEL DEGs) and DEGs from TCGA KIRC cohort (KIRC DEGs), yielding 27 overlapping candidates; (E) Cytoscape-based network analysis of the 27 candidate genes revealing functional clusters including lipid metabolic regulation; (F) Prognostic analysis of 24 candidate genes (three not available in GSCA) using TCGA-KIRC data showing associations with OS and PFS; (G–H) Expression analysis demonstrating reduced ACOX2 expression in ccRCC tissues compared with normal kidney tissues, confirmed in paired samples; (I) Kaplan–Meier survival curves showing higher ACOX2 expression associated with improved OS and PFS in KIRC patients; (J) Human Protein Atlas |
